Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Aug 19, 2021 7:50am
200 Views
Post# 33729108

Phase I...waiting....waiting....buffering....waiting?! :(

Phase I...waiting....waiting....buffering....waiting?! :(How much does Wanbang not give a f**k about SBM?  7 years later and now Howard has to "push" them to get results from a Phase I?  First off shouldn't have taken 7+ years to do a Phase I and now Howard has to nip at their heels to even get the results?  Doesn't sound like a very balanced or respectful partnership.  

On a separate note..... where the hell is some news?  Just how far off on his estimates was Howard?  Was supposed to have a pile of Milestones completed by May....then July...... then whenever.  So out of 1/2 dozen milestones laid out they couldn't complete anything?  Really need to get some management in there that knows what they are doing cause these guys have had enough time to show just how bad they are at this.  Thank goodness for the crew in France othewise this whole venture would be up the creek.  


TFC-039
Human Diabetes
Our partner, Wanbang Biopharmaceuticals, has informed us that our compound for type 2 diabetes (TFC-039) has completed their Phase I studies and the data is in the analysis phase. We expected to hear the results of this before the Chinese New Year in early February, however, they have experienced delays in the data analysis. We are now waiting and pushing to have a final report of these results and will update shareholders as soon as material information is available for release.

<< Previous
Bullboard Posts
Next >>